https://scholars.lib.ntu.edu.tw/handle/123456789/510571
標題: | Fixed dose of long-acting erythropoietic stimulating agents at higher frequency improves appetite, reduces inflammation and corrects anaemia in patients on haemodialysis | 作者: | Yen-Ting Lai Liu, Wen-Sheng ; Chu, Da-Chen ; Chan, Hsiang-Lin ; Li, Szu-Yuan ; Liu, Chih-Kuang ; Yang, Chih-Yu ; Chen, Yu-Wei ; Lee, Pui-Ching ; Lin, Chih-Ching |
關鍵字: | anaemia; dosing strategy; erythropoietin stimulating agent; haemodialysis; inflammation; malnutrition | 公開日期: | 2016 | 卷: | 43 | 期: | 10 | 起(迄)頁: | 875-882 | 來源出版物: | Clinical and Experimental Pharmacology and Physiology | 摘要: | Anaemia is an important issue in patients undergoing haemodialysis. We aimed to identify a better dosing schedule of a fixed monthly dose of continuous erythropoietin receptor activator (CERA) in patients with chronic kidney disease (CKD) on haemodialysis. The CERA dosing schedule included 100?μg once monthly for 2?months, 50?μg twice monthly for 2?months and then 100?μg once monthly for two months. The effectiveness was determined by comparing haematocrit, nutritional status (serum protein and albumin) and inflammatory markers (tumour necrosis factor (TNF)-α, interleukin (IL)-1, IL-6 and Hepcidin) at the beginning of the study with those at the end of the study. Forty-seven out of 67 patients completed the trial. At the end, haematocrit was significantly higher (34.51 vs 33.22%, P=.004), levels of inflammatory markers were significantly lower (TNF-α (30.71 vs 35.67?ng/mL, P=.007), IL-6 (5.12 vs 7.95?ng/mL, P=.033), hepcidin (60.39 vs 74.39?ng/mL, P=.002)), blood glucose levels were significantly lower (112.40 vs 139.02?mg/dL, P=.003) and albumin was significantly higher (4.11 vs 3.98, P=.001). Patients with a better than average response had a lower initial number of red blood cells (3.3 vs 3.6?×?106/mm3, P=.025) and a lower IL-1 (3.8 vs 12.9?ng/mL, P=.01). They also had significantly lower blood glucose levels at the end. (91.3 vs 124.0?mg/dL, P=.03). We demonstrate that a fixed monthly dose of CERA at a twice monthly dosing schedule improves nutrition, reduces the inflammation and corrects anaemia in patients on haemodialysis. This finding may provide a new strategy for treating CKD-related anaemia. ? 2016 John Wiley & Sons Australia, Ltd |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84984972132&doi=10.1111%2f1440-1681.12618&partnerID=40&md5=eb438dd3c83e269702fa033def8d1ba0 https://scholars.lib.ntu.edu.tw/handle/123456789/510571 |
DOI: | 10.1111/1440-1681.12618 | SDG/關鍵字: | albumin; calcium; chloride; continuous erythropoiesis receptor activator; glucose; hepcidin; interleukin 1; interleukin 6; phosphate; tumor necrosis factor; aged; albumin blood level; anemia; appetite; Article; autoanalyzer; calcium blood level; chloride blood level; chronic kidney disease; clinical article; erythrocyte; female; glucose blood level; hematocrit; hemodialysis; human; inflammation; leukocyte count; male; mean corpuscular hemoglobin; mean corpuscular volume; nutritional status; phosphate blood level; potassium blood level; thrombocyte count; treatment response |
顯示於: | 醫學院附設醫院 (臺大醫院) |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。